<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2959883-A1" country="EP" doc-number="2959883" kind="A1" date="20151230" family-id="52675509" file-reference-id="297627" date-produced="20180825" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="160452795" ucid="EP-2959883-A1"><document-id><country>EP</country><doc-number>2959883</doc-number><kind>A1</kind><date>20151230</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-14754873-A" is-representative="NO"><document-id mxw-id="PAPP193868558" load-source="docdb" format="epo"><country>EP</country><doc-number>14754873</doc-number><kind>A</kind><date>20140218</date><lang>KO</lang></document-id><document-id mxw-id="PAPP193868559" load-source="patent-office" format="original"><country>EP</country><doc-number>14754873.9</doc-number><date>20140218</date><lang>KO</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC162027983" ucid="KR-20130017446-A" load-source="docdb"><document-id format="epo"><country>KR</country><doc-number>20130017446</doc-number><kind>A</kind><date>20130219</date></document-id></priority-claim><priority-claim mxw-id="PPC162035048" ucid="KR-2014001289-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>KR</country><doc-number>2014001289</doc-number><kind>W</kind><date>20140218</date></document-id></priority-claim><priority-claim mxw-id="PPC162035940" ucid="KR-20140017627-A" load-source="docdb"><document-id format="epo"><country>KR</country><doc-number>20140017627</doc-number><kind>A</kind><date>20140217</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1919280471" load-source="docdb">A61K  31/164       20060101ALI20160707BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1919281423" load-source="docdb">A61Q  19/00        20060101ALI20160707BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1919283750" load-source="docdb">A61K  31/20        20060101ALI20160707BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1919284234" load-source="docdb">A61K   8/18        20060101AFI20160707BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1919287668" load-source="docdb">A61K  47/38        20060101ALI20160707BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1987765777" load-source="docdb" scheme="CPC">A61K   8/8182      20130101 FI20151219BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987766815" load-source="docdb" scheme="CPC">A61Q  19/00        20130101 LI20151219BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987767932" load-source="docdb" scheme="CPC">A61K   8/73        20130101 LI20150318BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987772194" load-source="docdb" scheme="CPC">A61K   8/8152      20130101 LI20150318BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987774500" load-source="docdb" scheme="CPC">A61K   8/30        20130101 LI20151217BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987775584" load-source="docdb" scheme="CPC">A61K   8/342       20130101 LI20151217BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987778145" load-source="docdb" scheme="CPC">A61K  31/20        20130101 LI20141024BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987779033" load-source="docdb" scheme="CPC">A61K   8/68        20130101 LI20151219BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987784899" load-source="docdb" scheme="CPC">A61K   8/361       20130101 LI20151219BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987788084" load-source="docdb" scheme="CPC">A61K2800/10        20130101 LA20151217BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987792322" load-source="docdb" scheme="CPC">A61K   8/731       20130101 LI20151219BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987794068" load-source="docdb" scheme="CPC">A61K   8/63        20130101 LI20151219BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987794189" load-source="docdb" scheme="CPC">A61K  31/575       20130101 LI20141024BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987796540" load-source="docdb" scheme="CPC">A61K2800/48        20130101 LA20151217BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987796723" load-source="docdb" scheme="CPC">A61K  31/164       20130101 LI20151219BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987798508" load-source="docdb" scheme="CPC">A61K   8/375       20130101 LI20151217BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT165549851" lang="DE" load-source="patent-office">EXTERN VERWENDETE ZUSAMMENSETZUNG FÜR SUBAZIDE HAUT UND KOSMETISCHER STOFF DAMIT</invention-title><invention-title mxw-id="PT165549852" lang="EN" load-source="patent-office">COMPOSITION EXTERNALLY USED FOR SUBACID SKIN AND COSMETIC MATERIAL INCLUDING SAME</invention-title><invention-title mxw-id="PT165549853" lang="FR" load-source="patent-office">COMPOSITION UTILISÉE PAR VOIE EXTERNE POUR PEAU SUB-ACIDE ET MATIÈRE COSMÉTIQUE ASSOCIÉE</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR1103344899" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>NEOPHARM CO LTD</last-name><address><country>KR</country></address></addressbook></applicant><applicant mxw-id="PPAR1103329952" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>NEOPHARM CO., LTD.</last-name></addressbook></applicant><applicant mxw-id="PPAR1101649187" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Neopharm Co., Ltd.</last-name><iid>101476070</iid><address><street>309-8 Techno2-ro Yuseong-gu</street><city>Daejeon 305-510</city><country>KR</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR1103305369" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>KIM SU-HWAN</last-name><address><country>KR</country></address></addressbook></inventor><inventor mxw-id="PPAR1103328642" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>KIM, SU-HWAN</last-name></addressbook></inventor><inventor mxw-id="PPAR1101653374" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>KIM, SU-HWAN</last-name><address><street>102-1303 Doansindoshi Sumokto Apt. 177 Doandong-Ro Seo-Gu</street><city>Daejeon 302-881</city><country>KR</country></address></addressbook></inventor><inventor mxw-id="PPAR1103328827" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>LEE SIN-HEE</last-name><address><country>KR</country></address></addressbook></inventor><inventor mxw-id="PPAR1103306702" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>LEE, Sin-Hee</last-name></addressbook></inventor><inventor mxw-id="PPAR1101643575" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>LEE, Sin-Hee</last-name><address><street>103-1301 Saedulmoe Humansia 1 dangi Apt. 137 Gyejok-Ro Dong-Gu</street><city>Daejeon 300-737</city><country>KR</country></address></addressbook></inventor><inventor mxw-id="PPAR1103322289" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>KIM YOON</last-name><address><country>KR</country></address></addressbook></inventor><inventor mxw-id="PPAR1103332648" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>KIM, YOON</last-name></addressbook></inventor><inventor mxw-id="PPAR1101649361" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>KIM, YOON</last-name><address><street>411-1107 Sunbimaul 4 Dangi Apt. 135 Gyejoksan-Ro Daedeok-Gu</street><city>Daejeon 306-778</city><country>KR</country></address></addressbook></inventor><inventor mxw-id="PPAR1103336722" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>JEONG SE-KYOO</last-name><address><country>KR</country></address></addressbook></inventor><inventor mxw-id="PPAR1103331008" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>JEONG, SE-KYOO</last-name></addressbook></inventor><inventor mxw-id="PPAR1101647232" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>JEONG, SE-KYOO</last-name><address><street>108-1304 Dungji Apt. 254 Cheongsa-Ro Seo-Gu</street><city>Daejeon 302-734</city><country>KR</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR1101645199" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>von Kreisler Selting Werner</last-name><iid>101166970</iid><address><street>Deichmannhaus am Dom Bahnhofsvorplatz 1</street><city>50667 Köln</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="KR-2014001289-W"><document-id><country>KR</country><doc-number>2014001289</doc-number><kind>W</kind><date>20140218</date><lang>KO</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2014129779-A1"><document-id><country>WO</country><doc-number>2014129779</doc-number><kind>A1</kind><date>20140828</date><lang>KO</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS660730920" load-source="docdb">AL</country><country mxw-id="DS660629332" load-source="docdb">AT</country><country mxw-id="DS660628258" load-source="docdb">BE</country><country mxw-id="DS660707757" load-source="docdb">BG</country><country mxw-id="DS660713810" load-source="docdb">CH</country><country mxw-id="DS660628263" load-source="docdb">CY</country><country mxw-id="DS660629333" load-source="docdb">CZ</country><country mxw-id="DS660730922" load-source="docdb">DE</country><country mxw-id="DS660628264" load-source="docdb">DK</country><country mxw-id="DS660628265" load-source="docdb">EE</country><country mxw-id="DS660706836" load-source="docdb">ES</country><country mxw-id="DS660707758" load-source="docdb">FI</country><country mxw-id="DS660713815" load-source="docdb">FR</country><country mxw-id="DS660730931" load-source="docdb">GB</country><country mxw-id="DS660628266" load-source="docdb">GR</country><country mxw-id="DS660730932" load-source="docdb">HR</country><country mxw-id="DS660629334" load-source="docdb">HU</country><country mxw-id="DS660713816" load-source="docdb">IE</country><country mxw-id="DS660628275" load-source="docdb">IS</country><country mxw-id="DS660707763" load-source="docdb">IT</country><country mxw-id="DS660628276" load-source="docdb">LI</country><country mxw-id="DS660707764" load-source="docdb">LT</country><country mxw-id="DS660790058" load-source="docdb">LU</country><country mxw-id="DS660707765" load-source="docdb">LV</country><country mxw-id="DS660707766" load-source="docdb">MC</country><country mxw-id="DS660790059" load-source="docdb">MK</country><country mxw-id="DS660790060" load-source="docdb">MT</country><country mxw-id="DS660790061" load-source="docdb">NL</country><country mxw-id="DS660713817" load-source="docdb">NO</country><country mxw-id="DS660790062" load-source="docdb">PL</country><country mxw-id="DS660706837" load-source="docdb">PT</country><country mxw-id="DS660628934" load-source="docdb">RO</country><country mxw-id="DS660706838" load-source="docdb">RS</country><country mxw-id="DS660790063" load-source="docdb">SE</country><country mxw-id="DS660730934" load-source="docdb">SI</country><country mxw-id="DS660713818" load-source="docdb">SK</country><country mxw-id="DS660713823" load-source="docdb">SM</country><country mxw-id="DS660628277" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>ME</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA166480893" lang="EN" load-source="patent-office"><p id="pa01" num="0001">The present invention relates to a composition with a pH of 3-5, preferably 3-4.5 externally used for a subacid skin composed of a multi-lamellar emulsion including pH modulation agent and a polymeric thickening agent, and a composition externally used for a subacid skin according to the present invention maintains stably a multi-lamellar emulsion with a skin barrier function composed of a large amount of a lipophilic skin care material at a relatively low pH condition so as to enhance or recover the skin barrier function through normalizing the skin pH, thus recovering and maintaining a healthy skin, making the skin effectively moisturized, maintaining a proper viscosity so as to prevent the phase separation, and having almost no skin penetration so as to eliminate the problem of stimulating the skin.<img id="iaf01" file="imgaf001.tif" wi="78" he="71" img-content="drawing" img-format="tif"/></p></abstract><abstract mxw-id="PA166760705" lang="EN" source="EPO" load-source="docdb"><p>The present invention relates to a composition with a pH of 3-5, preferably 3-4.5 externally used for a subacid skin composed of a multi-lamellar emulsion including pH modulation agent and a polymeric thickening agent, and a composition externally used for a subacid skin according to the present invention maintains stably a multi-lamellar emulsion with a skin barrier function composed of a large amount of a lipophilic skin care material at a relatively low pH condition so as to enhance or recover the skin barrier function through normalizing the skin pH, thus recovering and maintaining a healthy skin, making the skin effectively moisturized, maintaining a proper viscosity so as to prevent the phase separation, and having almost no skin penetration so as to eliminate the problem of stimulating the skin.</p></abstract><description mxw-id="PDES98405594" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b>Technical Field</b></heading><p id="p0001" num="0001">The present invention relates to a weakly acidic composition for skin external application, a multi-lamellar emulsion containing a ceramide, a sterol, a fatty acid, a higher alcohol and an emulsifier, a pH adjuster and a polymeric thickener, and a cosmetic formulation comprising the composition. More particularly, the present invention relates to a weakly acidic composition for skin external application, in which a multi-lamellar emulsion containing large amounts of dermatologically useful oleophilic substances and having skin barrier function is stably maintained at a relatively low pH, so that the composition can normalize the pH of the skin to enhance or restore the skin's barrier function to thereby restore and maintain the skin in a healthy state, and can effectively moisture the skin, and the composition is maintained at suitable viscosity so as to be effectively prevented from phase separation, and does not penetrate the skin, and thus causes no skin irritation, and to a cosmetic formulation comprising the composition.</p><heading id="h0002"><b>Background Art</b></heading><!-- EPO <DP n="2"> --><p id="p0002" num="0002">The epidermis of the skin consists of stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum and stratum basale layers. Among these layers, the stratum corneum (horny layer) forms the outermost layer of the skin, and is one of the most important portions of the human body, which functions as a primary barrier to prevent the loss of water from the body and protect the body from external harmful contaminants.</p><p id="p0003" num="0003">The horny layer is composed of keratinocytes and intercellular lipids. Herein, keratinocytes are cells derived from the stratum basale (basal layer) of the epidermis, and contain the protein keratin. Intercellular lipids are present between these keratinocytes and composed of ceramides, cholesterols, fatty acids, etc. These are present as a multi-lamellar structure and play a very important role in skin moisturization and protection by enhancement of the skin barrier, and the structure thereof can be observed by polarized optical microscopy.</p><p id="p0004" num="0004">This multi-lamellar structure was described first by Peter M. Elias through the "Brick and Mortar" model, and then proven through studies (<nplcit id="ncit0001" npl-type="s"><text>The Characterization of Molecular Organization of multilamellar Emulsions Containing Pseudoceramide and Type III Synthetic Ceramide. J Invest Dermatol. 2003 Oct; 121 (4) :794-801</text></nplcit>.).</p><p id="p0005" num="0005">Meanwhile, it was reported that, when the pH of the skin<!-- EPO <DP n="3"> --> is unsuitable or changes to neutral or alkaline pH values due to frequent washing or disease, the activity of lipase will decrease, and thus the synthesis of ceramides, cholesterols and fatty acids, which form intercellular lipids, will decrease, causing damage to the skin barrier (<nplcit id="ncit0002" npl-type="s"><text>Effects of soaps and detergents on skin surface pH, stratum corneum hydration and fat content in infants. Dermatology 1997; 195: 258-262</text></nplcit>). Moreover, it was reported that a neutral or weakly alkaline pH can result in the formation of conditions advantageous for the proliferation of skin flora, thus causing various skin diseases (<nplcit id="ncit0003" npl-type="s"><text>The effect of detergents on skin pH and its consequences. Clin Dermatol. 1996; 14(1): 23-27</text></nplcit>.). In addition, it was reported that an increase in the pH of the skin can result in the weakening of the skin barrier, thus causing skin troubles, sensitive skin, dry skin, and even atopy (<nplcit id="ncit0004" npl-type="s"><text>Abnormal skin barrier in the pathogenesis of atopic dermatitis. Peter M. Elias, M.D. University of California, San Francisco, CA 94121</text></nplcit>).</p><p id="p0006" num="0006">The skin of the human body should be maintained at a weakly acidic pH for the following reasons. First, at a weakly acidic pH, lipase that is involved in the synthesis of the constituent components of intercellular lipids forming the skin barrier is activated. This results in an increase in the synthesis of ceramides, cholesterols and fatty acids, which are the constituent components of intercellular lipids (<nplcit id="ncit0005" npl-type="s"><text>Stratum Corneum pH in Atopic Dermatitis. Am J Clin Dermatol 2004; 5<!-- EPO <DP n="4"> --> (4): 217-223</text></nplcit>). Second, the proliferation of normal flora on the skin surface is suppressed, the invasion of external bacteria is prevented, and thus the normal function of the skin barrier is maintained. Accordingly, maintaining the pH of the skin at a weakly acidic pH is important to make the skin moist, elastic and soft (<nplcit id="ncit0006" npl-type="s"><text>Skin barrier: Cutaneous barriers in defense against microbial invasion, Anna Di Nardo and Richard L. Gallo pp. 364-365</text></nplcit>).</p><p id="p0007" num="0007">Thus, a composition for skin external application, which has a multi-lamellar structure and a relatively weakly acidic pH, preferably a pH of about 3-5, more preferably about 3-4.5, has a function of enhancing the skin barrier, and also has the effect of maintaining the skin at a normal pH or restoring the skin to a normal pH. Thus, this composition makes a skin, which has damaged or reduced skin barrier function, healthy.</p><p id="p0008" num="0008">In the prior art, many cosmetic products for restoring the skin barrier function, which contain various ceramides, were disclosed, but most of these cosmetic products did not have a multi-lamellar structure, but contained active ingredients which were simply added and mixed, and thus the effects thereof were insignificant.</p><p id="p0009" num="0009">In addition, a multi-lamellar emulsion type cosmetic product containing ceramide was proposed by the applicant and is being sold, but the pH thereof is close to a neutral pH and is not weakly acidic.<!-- EPO <DP n="5"> --></p><p id="p0010" num="0010">However, if an organic acid is added to a cosmetic formulation to make the cosmetic formulation weakly acidic, the viscosity of the formulation will necessarily be reduced, and if the viscosity is reduced, the phase stability of the formulation will be reduced so that the time-dependent stability of the formulation will be reduced, thus causing phase separation. In addition, serious damage to the characteristic liquid crystal structure of the multi-lamellar emulsion will be caused. These problems are not satisfactorily solved even when a thickener is added.</p><p id="p0011" num="0011">If alpha-hydroxy acid (AHA) or beta-hydroxy acid (BHA) is added as the organic acid as described above, AHA in the former case can penetrate the skin to cause skin irritation and increase the photosensitivity of the skin. In addition, at a pH of less than, it is difficult to obtain a stable emulsion formulation. In the latter case, skin irritation is low, but still remains, and at a pH of less than 5, it is difficult to obtain a stable emulsion formulation.</p><p id="p0012" num="0012">If an acidic thickener is used in a formulation without adding the organic acid as described above, the pH of the formulation can become weakly acidic. However, at this weakly acidic pH, there are serious problems in that the inherent liquid crystal structure of the multi-lamellar structure is damaged and the viscosity of the formulation is also reduced. A reduction in the viscosity of the formulation leads to a<!-- EPO <DP n="6"> --> decrease in phase stability, resulting in phase separation.</p><p id="p0013" num="0013">Accordingly, there has been a need for the development of an effective cosmetic formulation that can effectively restore or enhance the skin barrier function of a skin having damaged or reduced skin barrier function by normalizing the pH of the skin and, at the same time, has high phase stability and causes little or no skin irritation.</p><heading id="h0003"><b>Disclosure</b></heading><heading id="h0004"><b>Technical Problem</b></heading><p id="p0014" num="0014">It is a first object of the present invention to provide a weakly acidic composition for skin external application, in which a multi-lamellar emulsion containing large amounts of dermatologically useful oleophilic substances and having a skin barrier function is stably maintained at a relatively low pH, so that the composition can normalize the pH of the skin to enhance or restore the skin's barrier function to thereby restore and maintain the skin in a healthy state and can effectively moisturize the skin.</p><p id="p0015" num="0015">A second object of the present invention is to provide a weakly acidic composition for skin external application, which can be maintained at suitable viscosity, and thus has high phase stability and high time-dependent stability so as to be effectively prevented from phase separation.</p><p id="p0016" num="0016">A third object of the present invention is to provide a<!-- EPO <DP n="7"> --> weakly acidic composition for skin external application, which has low skin penetrability, and thus causes little or no skin irritation.</p><p id="p0017" num="0017">A fourth object of the present invention is to provide a weakly acidic cosmetic formulation containing, as an active ingredient, the weakly acidic composition for skin external application described in the above objects.</p><heading id="h0005"><b>Technical Solution</b></heading><p id="p0018" num="0018">In order to accomplish the above objects, in accordance with a preferred aspect of the present invention, there is provided a weakly acidic composition for skin external application, which comprises: a multi-lamellar emulsion containing a ceramide, a sterol, a fatty acid, a higher alcohol and an emulsifier; a pH adjuster; and a polymeric thickener, the composition having a pH of 3-5, preferably 3-4.5.</p><p id="p0019" num="0019">In accordance with a preferred embodiment of the present invention, there is provided a weakly acidic composition for skin external application wherein the multi-lamellar emulsion is contained in an amount of 1.0-50.0 wt% based on the total weight of the composition.</p><p id="p0020" num="0020">In accordance with another preferred embodiment of the present invention, there is provided a weakly acidic composition for skin external application wherein the multi-lamellar<!-- EPO <DP n="8"> --> emulsion contains 0.01-5 wt% of the ceramide, 0.1-5 wt% of the sterol, 1-20 wt% of the fatty acid, 1-20 wt% of the higher alcohol, and 1-15 wt% of the emulsifier.</p><p id="p0021" num="0021">In accordance with still another preferred embodiment of the present invention, there is provided a weakly acidic composition for skin external application wherein the ceramide is at least one selected from the group consisting of ceramide-1, ceramide-3, ceramide-3B, ceramide-4, ceramide-6, myristoyl/palmitoyl oxostearamide/arachamide MEA, and dihydroxyisopropyl palmoylpalmamide; the sterol is at least one selected from the group consisting of cholesterol, cholesteryl acetate, cholesteryl sulfate, and phytosterol; the fatty acid or fatty alcohol is a fatty acid or fatty alcohol having 14 to 22 carbon atoms; and the emulsifier is at least one selected from the group consisting of hydrogenated lecithin, polyglyceryl fatty acid ester, sorbitan fatty acid ester, polyoxyethylene glyceryl fatty acid ester, alkyl glucoside, and polyoxyethylene sorbitan fatty acid ester.</p><p id="p0022" num="0022">In accordance with still another preferred embodiment of the present invention, there is provided a weakly acidic composition for skin external application wherein the pH adjuster is carbomer.</p><p id="p0023" num="0023">In accordance with still another preferred embodiment of the present invention, there is provided a weakly acidic composition for skin external application wherein the<!-- EPO <DP n="9"> --> polymeric thickener is at least one selected from the group consisting of hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose stearoxy ether, ammonium acryloyldimethyl taurate/VP copolymer, xanthan gum, and acrylate/alkyl acrylate crosspolymer.</p><p id="p0024" num="0024">In another preferred aspect of the present invention, there is provided a cosmetic formulation containing 1-99 wt% of the weakly acidic composition for skin external application.</p><heading id="h0006"><b>Advantageous Effects</b></heading><p id="p0025" num="0025">A weakly acidic composition for skin external application according to the present invention comprises a multi-lamellar emulsion containing large amounts of dermatologically useful oleophilic substances and having a skin barrier function, which is stably maintained even at a relatively low pH. Thus, the composition can normalize the pH of the skin to enhance or restore the skin's barrier function to thereby restore and maintain the skin in a healthy state and can effectively moisturize the skin. In addition, the composition according to the present invention can be maintained at suitable viscosity, and thus has high phase stability and high time-dependent stability so as to be effectively prevented from phase separation. Furthermore, the composition according to the present invention has low skin penetrability, and thus causes<!-- EPO <DP n="10"> --> little or no skin irritation. Thus, a weakly acidic cosmetic formulation comprising the composition according to the present invention contributes to normalizing the pH of a skin having damaged or reduced skin barrier function, activates lipase that is involved in the synthesis of lipids functioning as a skin barrier, thereby making keratinocytes stable, and inhibits the abnormal proliferation or invasion of skin flora to thereby maintain the skin in a healthy state.</p><heading id="h0007"><b>Description of Drawings</b></heading><p id="p0026" num="0026"><ul><li><figref idrefs="f0001 f0002">FIGS. 1 to 4</figref> are polarized microscope photographs of liquid crystals, which show the multi-lamellar emulsion structures of weakly acidic compositions for skin external application according to Examples of the present invention.</li><li><figref idrefs="f0003 f0004 f0005">FIGS. 5 to 9</figref> are polarized microscope photographs of weakly acidic compositions for skin external application according to Comparative Examples.</li></ul></p><heading id="h0008"><b>Best Mode</b></heading><p id="p0027" num="0027">The present invention provides a weakly acidic composition for skin external application, which comprises: a multi-lamellar emulsion containing a ceramide, a sterol, a fatty acid, a higher alcohol and an emulsifier; a pH adjuster; and a polymeric thickener, the composition having a pH of 3-5, preferably 3-4.5.<!-- EPO <DP n="11"> --></p><heading id="h0009"><b>Mode for Invention</b></heading><p id="p0028" num="0028">Hereinafter, the present invention will be described in detail.</p><p id="p0029" num="0029">The multi-lamellar emulsion that is used in the weakly acidic composition for skin external application according to the present invention contains a ceramide, a sterol, a fatty acid, a higher alcohol and an emulsifier.</p><p id="p0030" num="0030">The ceramide that is used in the multi-lamellar emulsion may be any one or more selected from among natural ceramides, including ceramide-1, ceramide-3, ceramide-3B, ceramide-4 and ceramide-6, and pseudoceramides synthesized by the applicant, for example, myristoyl/palmitoyl oxostearamide/arachamide MEA (trade name: PC-9S) and dihydroxy isopropyl palmoyl palmamide (trade name: PC-5). The content of the ceramide in the multi-lamellar emulsion is preferably 0.01-5 wt%.</p><p id="p0031" num="0031">The sterol that is used in the present invention has a fused ring structure, and thus contributes to maintaining the multi-lamellar emulsion. The sterol may be one or more selected from among cholesterol and its derivatives, including cholesteryl acetate, cholesteryl sulfate, stigmasterol, beta-sitosterol, ergosterol, and plant-derived phytosterol that is a mixture thereof. The content of the sterol in the multilamellar emulsion may be 0.1-5 wt%.</p><p id="p0032" num="0032">The fatty alcohol that is used in the present invention<!-- EPO <DP n="12"> --> may be any one or more selected from among fatty alcohols having 14 to 22 carbon atoms, and examples thereof include cetyl alcohol, stearyl alcohol, cetearyl alcohol, behenyl alcohol, etc. The content of the fatty alcohol in the multilamellar emulsion is preferably 1-20 wt%.</p><p id="p0033" num="0033">The fatty acid that is used in the present invention may be any one or more selected from among fatty acids having 14 to 22 carbon atoms, and examples thereof include myristic acid, palmitic acid, stearic acid, oleic acid, etc. The content of the fatty acid in the multi-lamellar emulsion is preferably 1-20 wt%.</p><p id="p0034" num="0034">The emulsifier that is used in the present invention may be selected from among hydrogenated lecithin, polyglyceryl fatty acid ester, sorbitan fatty acid ester, polyoxyethylene glyceryl fatty acid ester, alkyl glucoside, and polyoxyethylene sorbitan fatty acid ester. The content of the emulsifier in the multi-lamellar emulsion is preferably 1-15 wt%.</p><p id="p0035" num="0035">A multi-lamellar emulsion made of such components shows particular lamellar crystal phase when observed with a polarized microscope.</p><p id="p0036" num="0036">The role of the ceramide and the sterol in the above-described multi-lamellar emulsion is important.</p><p id="p0037" num="0037">This role will be explained below, and Table 1 below shows several examples of the multi-lamellar emulsion and the results of observation of formed liquid crystal phases.<!-- EPO <DP n="13"> --></p><p id="p0038" num="0038">The pH adjuster that is used in the present invention is particularly preferably carbomer having a carboxyl group in the structure, instead of an organic acid. Carbomer is a synthetic polymer made of acrylic acid or its derivative, and has an acrylic acid content of 56-58 wt%. An aqueous dispersion of 0.5-1.0 (w/v)% of carbomer has a pH of 2.5-3.5, and is effectively used to reduce the pH of the weakly acidic composition for skin external application according to the present invention. Meanwhile, caution is required because carbomer can cause the loss or reduction of consistency in the presence of a cationic polymer, acid or electrolyte.</p><p id="p0039" num="0039">If the carbomer is neutralized, it acts as a thickener, but the carbomer is not neutralized, it acts to stabilize the emulsion. In addition, because the carbomer is a polymer, it does not penetrate the skin, and thus does not cause side effects such as skin irritation.</p><p id="p0040" num="0040">If the carbomer is used as a pH adjuster or a pH lowering agent in the multi-lamellar emulsion, a reduction in the viscosity of the emulsion will occur to make it difficult to stabilize the emulsion. This problem cannot be solved with a conventional polymeric thickener.</p><p id="p0041" num="0041">The present inventors have conducted experiments on a wide range of selected polymeric thickeners, and as a result, have found that the use of hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose stearoxy ether,<!-- EPO <DP n="14"> --> ammonium acryloyldimethyl taurate/VP copolymer, acrylate/alkyl acrylate crosspolymer and xanthan gum alone or in combination, preferably one or more selected from hydroxypropylmethyl cellulose stearoxy ether, ammonium acryloyldimethyl taurate/VP copolymer and xanthan gum, particularly hydroxypropylmethyl cellulose stearoxy ether and/or ammonium acryloyldimethyl taurate/VP copolymer, can provide satisfactory results.</p><p id="p0042" num="0042">The content of the carbomer in the emulsion may vary depending on a desired pH, but is preferably 0.05-2 wt%. If the content of the carbomer is lower than the lower limit of the above range, a sufficient pH-lowering effect cannot be obtained, and if the content of the carbomer is higher than the upper limit of the above range, the pH and viscosity of the emulsion will deviate from desired values.</p><p id="p0043" num="0043">The thickener can be selectively used so that it can adjust the emulsion to a desired viscosity.</p><p id="p0044" num="0044">The weakly acidic composition for skin external application according to the present invention can be provided as a cosmetic formulation such as a basic cosmetic product or a makeup cosmetic product. Formulations of the basic cosmetic product include lotion, cream, essence, skin lotion, pack, massage cream, cleansing foam, cleansing water, cleansing oil and the like.</p><p id="p0045" num="0045">In addition, it is to be understood that additives that are generally used in the cosmetic field can be suitably added<!-- EPO <DP n="15"> --> according to the intended use.</p><heading id="h0010"><u>Examples and Experimental Examples</u></heading><p id="p0046" num="0046">Hereinafter, the present invention will be described in detail with reference to examples, comparative examples and experimental examples. It is to be understood, however, that these examples are for illustrative purposes and are not intended to limit the scope of the present invention.</p><heading id="h0011"><u>1. Preparation of multi-lamellar emulsion pre-mix</u></heading><p id="p0047" num="0047">In order to examine the effects of ceramide, sterol and fatty acid on the formation of a multi-lamellar emulsion, an emulsion was prepared, and the liquid crystal phase thereof was observed.</p><p id="p0048" num="0048">Whether the prepared emulsion easily formed a lamellar liquid crystal phase was evaluated based on the shape and frequency of a characteristic Maltese cross texture observed by a polarized microscope (Optiphto-2, manufactured by Nikon).</p><p id="p0049" num="0049">Criteria for the evaluation were as follows:
<ul><li>⊚: the percentage of the liquid crystal phase in formed emulsion particles is more than 80%;</li><li>○: the percentage of the liquid crystal phase in formed emulsion particles is 50-80%;</li><li>Δ : the percentage of the liquid crystal phase in formed emulsion particles is less than 50%;</li><li>x: the liquid crystal phase is not substantially formed.</li></ul><!-- EPO <DP n="16"> --></p><p id="p0050" num="0050">Oil phase components and an emulsifier were dissolved uniformly and emulsified at a temperature of 60 to 80°C for 10 minutes while hot purified water was added thereto. After completion of the emulsification, the emulsion was cooled to room temperature while it was stirred.</p><p id="p0051" num="0051">Prepared formulations and the results of observation of the liquid crystal phase are shown in Table 1 below.
<tables id="tabl0001" num="0001"><table frame="all"><title><u>Table 1: Formulation of multi-lamellar emulsion</u></title><tgroup cols="9"><colspec colnum="1" colname="col1" colwidth="60mm"/><colspec colnum="2" colname="col2" colwidth="18mm"/><colspec colnum="3" colname="col3" colwidth="18mm"/><colspec colnum="4" colname="col4" colwidth="18mm"/><colspec colnum="5" colname="col5" colwidth="18mm"/><colspec colnum="6" colname="col6" colwidth="28mm"/><colspec colnum="7" colname="col7" colwidth="28mm"/><colspec colnum="8" colname="col8" colwidth="28mm"/><colspec colnum="9" colname="col9" colwidth="28mm"/><thead><row><entry morerows="1" valign="top">Components</entry><entry namest="col2" nameend="col5" align="left" valign="top">Examples 1 to 4</entry><entry namest="col6" nameend="col9" align="left" valign="top">Comparative Examples 1 to 4</entry></row><row><entry valign="top">Example 1</entry><entry valign="top">Example 2</entry><entry valign="top">Example 3</entry><entry valign="top">Example 4</entry><entry valign="top">Comp. Example 1</entry><entry valign="top">Comp. Example 2</entry><entry valign="top">Comp. Example 3</entry><entry valign="top">Comp. Example 4</entry></row></thead><tbody><row><entry>PC-9S</entry><entry>3</entry><entry>3</entry><entry>3</entry><entry>-</entry><entry>-</entry><entry>0.1</entry><entry>-</entry><entry>-</entry></row><row><entry>Ceramide 3</entry><entry>-</entry><entry>-</entry><entry>-</entry><entry>3</entry><entry>-</entry><entry>-</entry><entry>0.1</entry><entry>-</entry></row><row><entry>Phytosterol</entry><entry>2</entry><entry>2</entry><entry>2</entry><entry>2</entry><entry>-</entry><entry>-</entry><entry>-</entry><entry>0.1</entry></row><row><entry>Stearic acid</entry><entry>5</entry><entry>5</entry><entry>5</entry><entry>5</entry><entry>5</entry><entry>5</entry><entry>5</entry><entry>5</entry></row><row><entry valign="middle">Cetearyl alcohol</entry><entry valign="middle">10</entry><entry valign="middle">10</entry><entry valign="middle">10</entry><entry valign="middle">10</entry><entry valign="middle">10</entry><entry valign="middle">10</entry><entry valign="middle">10</entry><entry valign="middle">10</entry></row><row><entry valign="middle">Capric/caprylic triglyceride</entry><entry valign="middle">10</entry><entry valign="middle">10</entry><entry valign="middle">10</entry><entry valign="middle">10</entry><entry valign="middle">10</entry><entry valign="middle">10</entry><entry valign="middle">10</entry><entry valign="middle">10</entry></row><row><entry valign="middle">Glyceryl fatty acid ester</entry><entry valign="middle">5</entry><entry valign="middle">5</entry><entry valign="middle">5</entry><entry valign="middle">5</entry><entry valign="middle">5</entry><entry valign="middle">5</entry><entry valign="middle">5</entry><entry valign="middle">5</entry></row><row><entry valign="middle">Polyglyceryl fatty acid ester</entry><entry valign="middle">5</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">5</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry></row><row><entry valign="middle">Sorbitan fatty acid ester</entry><entry valign="middle">-</entry><entry valign="middle">5</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">5</entry><entry valign="middle">-</entry><entry valign="middle">-</entry></row><row><entry valign="middle">Hydrogenated lecithin</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">5</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">5</entry><entry valign="middle">-</entry></row><row><entry valign="middle">PEG glyceryl fatty acid ester</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">5</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">5</entry></row><row><entry>Purified water</entry><entry>To 100</entry><entry>To 100</entry><entry>To 100</entry><entry>To 100</entry><entry>To 100</entry><entry>To 100</entry><entry>To 100</entry><entry>To 100</entry></row><row><entry valign="middle">Results of liquid crystal phase polarized microscope</entry><entry valign="middle">⊚</entry><entry valign="middle">⊚</entry><entry valign="middle">⊚</entry><entry valign="middle">○</entry><entry valign="middle">x</entry><entry valign="middle">Δ</entry><entry valign="middle">Δ</entry><entry valign="middle">Δ</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="17"> --></p><heading id="h0012"><u>2. Preparation of emulsion composition having low pH</u></heading><p id="p0052" num="0052">Using the multi-lamellar emulsions prepared as shown in Table 1 above, weakly acidic compositions for skin external application were prepared, and the pH, viscosity, liquid crystal phase, time-dependent stability, skin irritability and moisturizing ability of the prepared compositions were evaluated.</p><p id="p0053" num="0053">According to the components and contents shown in Table 2 below, the components were placed in a mixer, and heated, stirred and cooled, thereby preparing cosmetic formulations of the Examples and the Comparative Examples.
<tables id="tabl0002" num="0002"><table frame="all"><title><u>Table 2: Formulations for evaluation</u></title><tgroup cols="14"><colspec colnum="1" colname="col1" colwidth="28mm"/><colspec colnum="2" colname="col2" colwidth="11mm"/><colspec colnum="3" colname="col3" colwidth="11mm"/><colspec colnum="4" colname="col4" colwidth="11mm"/><colspec colnum="5" colname="col5" colwidth="11mm"/><colspec colnum="6" colname="col6" colwidth="11mm"/><colspec colnum="7" colname="col7" colwidth="11mm"/><colspec colnum="8" colname="col8" colwidth="11mm"/><colspec colnum="9" colname="col9" colwidth="11mm"/><colspec colnum="10" colname="col10" colwidth="11mm"/><colspec colnum="11" colname="col11" colwidth="11mm"/><colspec colnum="12" colname="col12" colwidth="11mm"/><colspec colnum="13" colname="col13" colwidth="11mm"/><colspec colnum="14" colname="col14" colwidth="11mm"/><thead><row><entry morerows="1" valign="top">Components</entry><entry namest="col2" nameend="col5" align="left" valign="top">Example 5 to 8</entry><entry namest="col6" nameend="col14" align="left" valign="top">Comparative Example 5 to 13</entry></row><row><entry valign="top">5</entry><entry valign="top">6</entry><entry valign="top">7</entry><entry valign="top">8</entry><entry valign="top">5</entry><entry valign="top">6</entry><entry valign="top">7</entry><entry valign="top">8</entry><entry valign="top">9</entry><entry valign="top">10</entry><entry valign="top">11</entry><entry valign="top">12</entry><entry valign="top">13</entry></row></thead><tbody><row><entry valign="middle">Composition of Example 1</entry><entry valign="middle">30</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">30</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">30</entry></row><row><entry valign="middle">Composition of Example 2</entry><entry valign="middle">-</entry><entry valign="middle">30</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">30</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry></row><row><entry valign="middle">Composition of Example 3</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">30</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">30</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry></row><row><entry valign="middle">Composition of Example 4</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">30</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">30</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry></row><row><entry valign="middle">Composition of Comparative Example 1</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">30</entry><entry valign="middle">-</entry><entry valign="middle">30</entry><entry valign="middle">-</entry><entry valign="middle">-</entry></row><row><entry valign="middle">Composition of Comparative Example 2</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">30</entry><entry valign="middle">-</entry><entry valign="middle">30</entry><entry valign="middle">-</entry></row><row><entry>Glycerin</entry><entry>10</entry><entry>10</entry><entry>10</entry><entry>10</entry><entry>10</entry><entry>10</entry><entry>10</entry><entry>10</entry><entry>10</entry><entry>10</entry><entry>10</entry><entry>10</entry><entry>10</entry></row><row><entry>Carbomer</entry><entry>0.4</entry><entry>0.4</entry><entry>0.4</entry><entry>0.4</entry><entry>-</entry><entry>-</entry><entry>-</entry><entry>-</entry><entry>0.4</entry><entry>0.4</entry><entry>-</entry><entry>-</entry><entry>-</entry></row><row><entry>Lactic acid</entry><entry>-</entry><entry>-</entry><entry>-</entry><entry>-</entry><entry>0.8</entry><entry>0.8</entry><entry>0.8</entry><entry>0.8</entry><entry>0.2</entry><entry>0.2</entry><entry>0.8</entry><entry>0.8</entry><entry>-</entry></row><!-- EPO <DP n="18"> --><row><entry>Xanthan gum</entry><entry>0.1</entry><entry>-</entry><entry>-</entry><entry>-</entry><entry>0.3</entry><entry>-</entry><entry>0.3</entry><entry>-</entry><entry>0.3</entry><entry>0.3</entry><entry>0.3</entry><entry/><entry>0.3</entry></row><row><entry valign="middle">Hydroxypropyl methyl cellulose stearoxy ether</entry><entry valign="middle">0.1</entry><entry valign="middle">0.3</entry><entry valign="middle">-</entry><entry valign="middle">0.1</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry></row><row><entry valign="middle">Ammonium acryloyl dimethyl tauate/VP copolymer</entry><entry valign="middle">0.1</entry><entry valign="middle">-</entry><entry valign="middle">0.3</entry><entry valign="middle">0.2</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry></row><row><entry valign="middle">Preservative</entry><entry valign="middle">q.s.</entry><entry valign="middle">q.s.</entry><entry valign="middle">q.s.</entry><entry valign="middle">q.s.</entry><entry valign="middle">q.s.</entry><entry valign="middle">q.s.</entry><entry valign="middle">q.s.</entry><entry valign="middle">q.s.</entry><entry valign="middle">q.s.</entry><entry valign="middle">q.s.</entry><entry valign="middle">q.s.</entry><entry valign="middle">q.s.</entry><entry valign="middle">q.s.</entry></row><row><entry valign="middle">Sodium hydroxide</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">-</entry><entry valign="middle">q.s.</entry></row><row><entry>Purified water</entry><entry valign="middle">to 100</entry><entry valign="middle">to 100</entry><entry valign="middle">to 100</entry><entry valign="middle">to 100</entry><entry valign="middle">to 100</entry><entry valign="middle">to 100</entry><entry valign="middle">to 100</entry><entry valign="middle">to 100</entry><entry valign="middle">to 100</entry><entry valign="middle">to 100</entry><entry valign="middle">to 100</entry><entry valign="middle">to 100</entry><entry valign="middle">to 100</entry></row></tbody></tgroup></table></tables></p><heading id="h0013">1) Evaluation of liquid crystal phase</heading><p id="p0054" num="0054">According to the above evaluation criteria, the liquid crystal phase of the prepared samples was observed with a polarized microscope.</p><p id="p0055" num="0055">The results of the measurement are shown in Table 3 below. <figref idrefs="f0001 f0002">FIGS. 1 to 4</figref> show polarized microscope photographs of the formulations of Examples 5 to 8, respectively, and <figref idrefs="f0003 f0004 f0005">FIGS. 5 to 9</figref> show polarized microscope photographs of the formulation of Comparative Examples 5, 6, 11 12 and 13, respectively.</p><p id="p0056" num="0056">As can be seen therein, in the case in which carbomer and the thickener were used in the pre-mix that sufficiently formed the multi-lamellar emulsion, the liquid crystal phase was maintained in the same manner. However, in the case in which lactic acid was used as the organic acid, the liquid crystal phase was slightly poor, and the pre-mixes that did not<!-- EPO <DP n="19"> --> properly form the liquid crystal phase in the initial stage also showed a poor state. In addition, in the case in which xanthan gum was used as a thickener in the composition of Example 1 without using carbomer or the organic acid, a good liquid crystal phase appeared.</p><heading id="h0014">2) pH and viscosity</heading><p id="p0057" num="0057">pH was measured on an undiluted sample using a pH meter (Model 520, Orion), and viscosity was measured using a DV-2 viscometer (Brookfield) under the conditions of spindle #6, 20 rpm and 1 minute.</p><p id="p0058" num="0058">The results of measurement of pH indicated that all the formulations, excluding Comparative Example 13 in which pH was adjusted, showed a weakly acidic pH of 3-4.</p><p id="p0059" num="0059">Viscosity was significantly lower in the Comparative Examples than in the Examples.
<tables id="tabl0003" num="0003"><table frame="all"><title><u>Table 3: Results of measurement of pH and viscosity</u></title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="38mm"/><colspec colnum="2" colname="col2" colwidth="10mm"/><colspec colnum="3" colname="col3" colwidth="25mm"/><colspec colnum="4" colname="col4" colwidth="40mm"/><colspec colnum="5" colname="col5" colwidth="10mm"/><colspec colnum="6" colname="col6" colwidth="25mm"/><thead><row><entry valign="top">Samples</entry><entry valign="top">pH</entry><entry valign="top">Viscosity (cps)</entry><entry valign="top">Samples</entry><entry valign="top">pH</entry><entry valign="top">Viscosity (cps)</entry></row></thead><tbody><row><entry>Example 5</entry><entry valign="middle">3.3</entry><entry valign="middle">10,100</entry><entry valign="middle">Comparative Example 8</entry><entry valign="middle">3.2</entry><entry valign="middle">5,500</entry></row><row><entry>Example 6</entry><entry valign="middle">3.4</entry><entry valign="middle">12,300</entry><entry valign="middle">Comparative Example 9</entry><entry valign="middle">3.5</entry><entry valign="middle">9,600</entry></row><row><entry>Example 7</entry><entry valign="middle">3.4</entry><entry valign="middle">13,500</entry><entry valign="middle">Comparative Example 10</entry><entry valign="middle">3.4</entry><entry valign="middle">10,800</entry></row><row><entry>Example 8</entry><entry valign="middle">3.5</entry><entry valign="middle">13,000</entry><entry valign="middle">Comparative Example 11</entry><entry valign="middle">3.3</entry><entry valign="middle">4,200</entry></row><row><entry valign="middle">Comparative Example 5</entry><entry valign="middle">3.2</entry><entry valign="middle">3,600</entry><entry valign="middle">Comparative Example 12</entry><entry valign="middle">3.4</entry><entry valign="middle">4,400</entry></row><row><entry valign="middle">Comparative Example 6</entry><entry valign="middle">3.3</entry><entry valign="middle">4,900</entry><entry valign="middle">Comparative Example 13</entry><entry valign="middle">6.8</entry><entry valign="middle">11,500</entry></row><!-- EPO <DP n="20"> --><row><entry valign="middle">Comparative Example 7</entry><entry valign="middle">3.3</entry><entry valign="middle">4,700</entry><entry valign="middle"/><entry valign="middle"/><entry valign="middle"/></row></tbody></tgroup></table></tables></p><heading id="h0015">3) Test for time-dependent stability of formulations</heading><p id="p0060" num="0060">The samples were placed in opaque containers and stored in incubators at 45°C and 4°C and in a temperature cycling chamber (45°C↔5°C; once a day) for 12 weeks, and then the degrees of phase separation and discoloration were evaluated on a four-point scale as follows. The results of the evaluation are shown in Table 4 below.</p><p id="p0061" num="0061">Criteria for evaluation of formulation separation and discoloration:
<ul><li>0: no change;</li><li>1: very slight separation (discoloration);</li><li>2: slight separation (discoloration);</li><li>3: severe separation (discoloration).</li></ul>
<tables id="tabl0004" num="0004"><table frame="all"><title><u>Table 4: Results of time-dependent stability test</u></title><tgroup cols="14"><colspec colnum="1" colname="col1" colwidth="38mm"/><colspec colnum="2" colname="col2" colwidth="9mm"/><colspec colnum="3" colname="col3" colwidth="9mm"/><colspec colnum="4" colname="col4" colwidth="9mm"/><colspec colnum="5" colname="col5" colwidth="9mm"/><colspec colnum="6" colname="col6" colwidth="8mm"/><colspec colnum="7" colname="col7" colwidth="8mm"/><colspec colnum="8" colname="col8" colwidth="8mm"/><colspec colnum="9" colname="col9" colwidth="8mm"/><colspec colnum="10" colname="col10" colwidth="8mm"/><colspec colnum="11" colname="col11" colwidth="9mm"/><colspec colnum="12" colname="col12" colwidth="9mm"/><colspec colnum="13" colname="col13" colwidth="9mm"/><colspec colnum="14" colname="col14" colwidth="9mm"/><thead><row><entry morerows="1" valign="top">Temperature conditions</entry><entry namest="col2" nameend="col5" align="left" valign="top">Examples 5 to 8</entry><entry namest="col6" nameend="col14" align="left" valign="top">Comparative Examples 5 to 13</entry></row><row><entry valign="top">5</entry><entry valign="top">6</entry><entry valign="top">7</entry><entry valign="top">8</entry><entry valign="top">5</entry><entry valign="top">6</entry><entry valign="top">7</entry><entry valign="top">8</entry><entry valign="top">9</entry><entry valign="top">10</entry><entry valign="top">11</entry><entry valign="top">12</entry><entry valign="top">13</entry></row></thead><tbody><row><entry>45°C</entry><entry>0</entry><entry>1</entry><entry>0</entry><entry>0</entry><entry>2</entry><entry>2</entry><entry>3</entry><entry>2</entry><entry>2</entry><entry>2</entry><entry>3</entry><entry>2</entry><entry>0</entry></row><row><entry>4°C</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>1</entry><entry>1</entry><entry>1</entry><entry>1</entry><entry>0</entry><entry>0</entry><entry>1</entry><entry>1</entry><entry>0</entry></row><row><entry>45°C↔5°C cycling</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>2</entry><entry>2</entry><entry>3</entry><entry>3</entry><entry>3</entry><entry>2</entry><entry>3</entry><entry>2</entry><entry>0</entry></row></tbody></tgroup></table></tables></p><p id="p0062" num="0062">As can be seen in Table 4 above, in the case of the<!-- EPO <DP n="21"> --> Examples in which the pH of the pre-mixes that sufficiently formed the multi-lamellar emulsion was adjusted using carbomer and in which a separate thickener was used, the formulations were stable at all 45°C, 4°C and 45°C↔5°C cycling. However, in the compositions in which the formation of the multi-lamellar emulsion itself was incomplete or the pH was adjusted with the organic acid, a separation phenomenon appeared at 45°C and the cycling temperature.</p><heading id="h0016">4) Skin irritation evaluation (patch test)</heading><p id="p0063" num="0063">In order to evaluate the skin irritability of the compositions prepared in the Examples and the Comparative Examples, a closed patch test was performed on 10 healthy adult men and women.</p><p id="p0064" num="0064">Specifically, about 0.5 g of a 1% solution of each sample was added to a chamber, and then attached to the skin using square filter paper having a size of 0.5 cm<sup>2</sup> over 4 hours while preventing the loss of the sample, followed by removal of the chamber. At about 1 hour after removal of the chamber, the irritation degree and irritation response of the skin were evaluated by three professional panels according to the criteria shown in Table 5 below, and the skin irritation index was calculated using the following equation. The results of the evaluation are shown in Table 6 below.<!-- EPO <DP n="22"> -->
<tables id="tabl0005" num="0005"><table frame="all"><title><u>Table 5: Criteria for evaluation of skin irritation</u></title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="27mm"/><colspec colnum="2" colname="col2" colwidth="30mm"/><colspec colnum="3" colname="col3" colwidth="110mm"/><thead><row><entry valign="top">Irritation degree</entry><entry valign="top">Irritation response</entry><entry valign="top">Criteria for evaluation</entry></row></thead><tbody><row><entry>0</entry><entry>--</entry><entry>No symptom</entry></row><row><entry>2</entry><entry>-</entry><entry>Formation of erythema having a size of about 0.1 cm<sup>2</sup></entry></row><row><entry>4</entry><entry>-+</entry><entry>Formation of erythema and edema having a size of about 0.2 cm<sup>2</sup></entry></row><row><entry>6</entry><entry>+</entry><entry>Formation of erythema and edema having a size of about 0.3 cm<sup>2</sup>, and formation of blister</entry></row><row><entry>8</entry><entry>++</entry><entry>Formation of erythema and edema having a size of about 0.4 cm<sup>2</sup>, and formation of blister having a size of about 0.3 cm<sup>2</sup></entry></row><row><entry>10</entry><entry>+++</entry><entry>Formation of large blister having a size of more than 0.3 cm<sup>2</sup></entry></row></tbody></tgroup></table></tables>
<maths id="math0001" num=""><math display="block"><mrow><mtable columnalign="left"><mtr><mtd><munder><mrow><mi>Equation</mi></mrow><mo>̲</mo></munder></mtd></mtr><mtr><mtd><mi>Skin irritation index</mi><mo>=</mo><mi>irritation degree</mi><mo>×</mo><mi>number of subjects showing irritattion response</mi><mo>/</mo><mi>total number of subjects</mi></mtd></mtr></mtable></mrow></math><img id="ib0001" file="imgb0001.tif" wi="153" he="21" img-content="math" img-format="tif"/></maths>
<tables id="tabl0006" num="0006"><table frame="all"><title><u>Table 6: Results of skin irritation evaluation</u></title><tgroup cols="7"><colspec colnum="1" colname="col1" colwidth="40mm"/><colspec colnum="2" colname="col2" colwidth="13mm"/><colspec colnum="3" colname="col3" colwidth="12mm"/><colspec colnum="4" colname="col4" colwidth="12mm"/><colspec colnum="5" colname="col5" colwidth="12mm"/><colspec colnum="6" colname="col6" colwidth="12mm"/><colspec colnum="7" colname="col7" colwidth="31mm"/><thead><row><entry morerows="1" valign="top">Samples</entry><entry namest="col2" nameend="col6" align="left" valign="top">Evaluation results (number of persons)</entry><entry morerows="1" valign="top">Skin irritation index</entry></row><row><entry valign="top">++</entry><entry valign="top">+</entry><entry valign="top">+-</entry><entry valign="top">-</entry><entry valign="top">--</entry></row></thead><tbody><row><entry>Example 5</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>10</entry><entry>0.00</entry></row><row><entry>Example 6</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>10</entry><entry>0.00</entry></row><row><entry>Example 7</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>10</entry><entry>0.00</entry></row><row><entry>Example 8</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>10</entry><entry>0.00</entry></row><row><entry valign="middle">Comparative Example 5</entry><entry valign="middle">0</entry><entry valign="middle">0</entry><entry valign="middle">1</entry><entry valign="middle">2</entry><entry valign="middle">7</entry><entry valign="middle">2.80</entry></row><row><entry valign="middle">Comparative Example 6</entry><entry valign="middle">0</entry><entry valign="middle">1</entry><entry valign="middle">0</entry><entry valign="middle">1</entry><entry valign="middle">8</entry><entry valign="middle">2.80</entry></row><row><entry valign="middle">Comparative Example 7</entry><entry valign="middle">0</entry><entry valign="middle">2</entry><entry valign="middle">0</entry><entry valign="middle">1</entry><entry valign="middle">7</entry><entry valign="middle">3.40</entry></row><row><entry valign="middle">Comparative Example 8</entry><entry valign="middle">0</entry><entry valign="middle">1</entry><entry valign="middle">0</entry><entry valign="middle">2</entry><entry valign="middle">7</entry><entry valign="middle">3.00</entry></row><row><entry>Comparative Example 13</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>10</entry><entry>0.00</entry></row></tbody></tgroup><!-- EPO <DP n="23"> --></table></tables></p><p id="p0065" num="0065">As can be seen from the results in Table 6 above, the Examples of the present invention showed lower skin irritation indices than those of the Comparative Examples. In addition, the sample, to which a separate acidic additive was not added and the pH of which was adjusted to 6.8, also showed no skin irritation.</p><heading id="h0017">5) Evaluation of skin moisturizing ability</heading><p id="p0066" num="0066">In order to evaluate the skin moisturizing ability of the samples of the Examples and the Comparative Examples, the content of water in the horny layer of each of 20 adult women was measured using a Corneometer (CM825, Courage-Khazaka Electronic GmbH, Germany). The measurement was performed for 12 hours after application, and the change in the content of water in the horny layer of the skin was calculated using the following equation: <maths id="math0002" num=""><math display="block"><mrow><mi>Change of skin hydration</mi><mo>=</mo><mi>skin hydration after certain time</mi><mo>-</mo><mi>skin hydration before skin barrier damage</mi></mrow></math><img id="ib0002" file="imgb0002.tif" wi="153" he="13" img-content="math" img-format="tif"/></maths></p><p id="p0067" num="0067">The results of the measurement are shown in Table 7 below.
<tables id="tabl0007" num="0007"><table frame="all"><title><u>Table 7: Results of measurement of water retention rate</u></title><tgroup cols="10"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="9mm"/><colspec colnum="3" colname="col3" colwidth="9mm"/><colspec colnum="4" colname="col4" colwidth="9mm"/><colspec colnum="5" colname="col5" colwidth="9mm"/><colspec colnum="6" colname="col6" colwidth="9mm"/><colspec colnum="7" colname="col7" colwidth="9mm"/><colspec colnum="8" colname="col8" colwidth="9mm"/><colspec colnum="9" colname="col9" colwidth="9mm"/><colspec colnum="10" colname="col10" colwidth="9mm"/><thead><row><entry morerows="1" valign="top">Measurement results</entry><entry namest="col2" nameend="col5" align="left" valign="top">Examples</entry><entry namest="col6" nameend="col10" align="left" valign="top">Comparative Examples</entry></row><row><entry valign="top">5</entry><entry valign="top">6</entry><entry valign="top">7</entry><entry valign="top">8</entry><entry valign="top">5</entry><entry valign="top">6</entry><entry valign="top">11</entry><entry valign="top">12</entry><entry valign="top">13</entry></row></thead><tbody><row><entry valign="middle">Water retention rate</entry><entry valign="middle">54</entry><entry valign="middle">48</entry><entry valign="middle">47</entry><entry valign="middle">46</entry><entry valign="middle">38</entry><entry valign="middle">34</entry><entry valign="middle">31</entry><entry valign="middle">34</entry><entry valign="middle">43</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="24"> --></p><p id="p0068" num="0068">As can be seen from the results in Table 7 above, the use of carbomer and the multi-lamellar emulsion composition in combination showed a higher water retention rate compared to the use of the organic acid.</p><heading id="h0018">6) Evaluation of skin barrier function</heading><p id="p0069" num="0069">In order to evaluate the effects of the samples of Examples 1 to 3 and Comparative Example 13 on a change in the pH of the skin surface and the skin's barrier function, the following experiment was performed.</p><p id="p0070" num="0070">Each of the samples of Examples 1 to 3 and Comparative Example 13 was applied once to the inside of the upper arm of each of twenty 25-35-year-old women, and then the change in the pH of the skin surface between before and after application was measured. The pH of the skin surface was measured using MPA5 (Courage &amp; Khazaka Electronic GmbH, Germany) equipped with flat type electrodes, and the change in the pH of the skin surface after applying each of the samples of Examples 1 to 3 and Comparative Example 13 twice a day for 1 week was observed. Although the skin to which each of the samples of Examples 1, 2 and 3 was applied showed a slightly low pH, this difference was not significant. The results of the measurement are shown in Table 8 below.</p><p id="p0071" num="0071">Statistical analysis was performed by two-tailed student's t-test, and a P value &lt; 0.05 was considered statistically significant.<!-- EPO <DP n="25"> -->
<tables id="tabl0008" num="0008"><table frame="all"><title><u>Table 8: Measurement results for pH</u><u>of skin surface (mean ± SD) (p values are statistical analysis results with values before application)</u></title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="38mm"/><colspec colnum="2" colname="col2" colwidth="43mm"/><colspec colnum="3" colname="col3" colwidth="43mm"/><colspec colnum="4" colname="col4" colwidth="43mm"/><thead><row><entry valign="top">Samples</entry><entry valign="top">Before application</entry><entry valign="top">After one-time application</entry><entry valign="top">After application for 1 week</entry></row></thead><tbody><row><entry>Example 1</entry><entry>5.44 ± 0.193</entry><entry>5.42 ± 0.182</entry><entry>5.35 ± 0.110 (p=0.078)</entry></row><row><entry>Example 2</entry><entry>5.47 ± 0.166</entry><entry>5.43 ± 0.125</entry><entry>5.39 ± 0.109 (p=0.080)</entry></row><row><entry>Example 3</entry><entry>5.46 ± 0.198</entry><entry>5.40 ± 0.159</entry><entry>5.37 ± 0.122 (pH.092)</entry></row><row><entry>Comparative Example 13</entry><entry>5.47 ± 0.178</entry><entry>5.44 ± 0.139</entry><entry>5.49 ± 0.141 (pH.069)</entry></row></tbody></tgroup></table></tables></p><p id="p0072" num="0072">The inside of the upper arm of each of the same test subjects was scrubbed with general cleaning soap for 30 seconds twice a day to make bubbles, and then washed with running water for 1 minutes and dried with paper towels.</p><p id="p0073" num="0073">At 30 minutes after washing, each of the samples of Examples 1 to 3 and Comparative Example 13 was applied to the upper arm. After the same procedure was continued for 1 week, the change in the pH of the skin surface and the change in the skin's barrier function were measured. As a result, it could be seen that the pH of the skin surface in the portion to which the sample of Comparative Example 13 was applied statistically significantly increased, whereas the portion to which the sample of Example 1, 2 or 3 was applied showed no significant increase in the pH of the skin surface compared to before application.</p><p id="p0074" num="0074">To evaluate the skin barrier function, trans-epidermal water loss (TEWL) was measured using Tewameter TM210 (Courage &amp;<!-- EPO <DP n="26"> --> Khazaka Electronic GmbH, Germany).</p><p id="p0075" num="0075">Measurement was performed before application and for 10 days after application, and as a result, all the portions to which Examples 1 to 3 and Comparative Example 13 were applied showed no significant difference between before and after application.</p><p id="p0076" num="0076">To evaluate the stability of the skin barrier function of the applied portions, the TEWL level was measured while the horny layer in each of the applied portions was repeatedly removed using a D-Squame tape (CuDerm Corporation, Dallas, TX, USA). As a result, it was shown that the increase in the TEWL level in the portion to which each of Examples 1 to 3 was significantly lower than that in the portion to which Comparative Example 13 was applied.</p><p id="p0077" num="0077">Such results indicate that the samples of Examples 1 to 3 have the effect of increasing the stability of skin's barrier function. The results of the measurement are shown in Tables 9 and 10 below.
<tables id="tabl0009" num="0009"><table frame="all"><title><u>Table 9: pH measurement results (mean ± SD) obtained after application of samples after long-term use of soap</u></title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="53mm"/><colspec colnum="2" colname="col2" colwidth="50mm"/><colspec colnum="3" colname="col3" colwidth="54mm"/><thead><row><entry valign="top">Samples</entry><entry valign="top">Before application</entry><entry valign="top">After one-week application</entry></row></thead><tbody><row><entry>Example 1</entry><entry>5.45 ± 0.199</entry><entry>5.57 ± 0.198 (p=0.063)</entry></row><row><entry>Example 2</entry><entry>5.45 ± 0.244</entry><entry>5.58 ± 0.207 (p=0.077)</entry></row><row><entry>Example 3</entry><entry>5.45 ± 0.226</entry><entry>5.59 ± 0.243 (p=0.067)</entry></row><row><entry>Comparative Example 13</entry><entry>5.45 ± 0.221</entry><entry>5.90 ± 0.244 (p=4.94E-07)</entry></row></tbody></tgroup><tgroup cols="3" rowsep="0"><colspec colnum="1" colname="col1" colwidth="53mm"/><colspec colnum="2" colname="col2" colwidth="50mm"/><colspec colnum="3" colname="col3" colwidth="54mm"/><tbody><row><entry namest="col1" nameend="col3" align="justify">p values are statistical analysis results with values<!-- EPO <DP n="27"> --> before application</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0010" num="0010"><table frame="all"><title><u>Table 10: TEWL measurement results (mean ± SD) (g/hm</u><sup><u>2</u></sup><u>) for evaluation of stability of skin barrier</u></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="35mm"/><colspec colnum="2" colname="col2" colwidth="23mm"/><colspec colnum="3" colname="col3" colwidth="35mm"/><colspec colnum="4" colname="col4" colwidth="37mm"/><colspec colnum="5" colname="col5" colwidth="37mm"/><thead><row><entry valign="top">Samples</entry><entry valign="top">Before damage</entry><entry valign="top">After 5-time application</entry><entry valign="top">After 10-time application</entry><entry valign="top">After 15-time application</entry></row></thead><tbody><row><entry>Example 1</entry><entry>11.49 ± 1.852</entry><entry>15.01 ± 2.115</entry><entry>19.40 ± 1.933</entry><entry>25.17 ± 2.338</entry></row><row><entry>Example 2</entry><entry>11.41 ± 2.074</entry><entry>15.11 ± 1.957</entry><entry>19.76 ± 1.736</entry><entry>25.36 ± 1.816</entry></row><row><entry>Example 3</entry><entry>11.50 ± 1.800</entry><entry>15.36 ± 2.311</entry><entry>19.89 ± 1.760</entry><entry>25.26 ± 1.694</entry></row><row><entry valign="middle">Comparative Example 13</entry><entry valign="middle">11.63 ± 1.630</entry><entry valign="middle">19.46 ± 2.408</entry><entry valign="middle">25.58 ± 2.506</entry><entry valign="middle">32.38 ± 2.451</entry></row></tbody></tgroup></table></tables></p><heading id="h0019"><b>Industrial Applicability</b></heading><p id="p0078" num="0078">As described above, the weakly acidic cosmetic formulation according to the present invention contributes to normalizing the pH of a skin having damaged or reduced skin barrier function, activates lipase that is involved in the synthesis of lipids functioning as a skin barrier, thereby making keratinocytes stable, and inhibits the abnormal proliferation or invasion of skin flora or external bacteria to thereby maintain the skin in a healthy state.</p></description><claims mxw-id="PCLM90460559" lang="EN" load-source="patent-office"><!-- EPO <DP n="28"> --><claim id="c-en-0001" num="0001"><claim-text>A weakly acidic composition for skin external application, comprising: a multi-lamellar emulsion containing a ceramide, a sterol, a fatty acid, a higher alcohol and an emulsifier; a pH adjuster; and a polymeric thickener, the composition having a pH of 3-5.</claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>The weakly acidic composition of claim 1, wherein the multi-lamellar emulsion is contained in an amount of 1.0-50.0 wt% based on the total weight of the composition.</claim-text></claim><claim id="c-en-0003" num="0003"><claim-text>The weakly acidic composition of claim 2, wherein the multi-lamellar emulsion contains 0.01-5 wt% of the ceramide, 0.1-5 wt% of the sterol, 1-20 wt% of the fatty acid, 1-20 wt% of the higher alcohol, 1-15 wt% of the emulsifier, and a balance of purified water.</claim-text></claim><claim id="c-en-0004" num="0004"><claim-text>The weakly acidic composition of claim 2, wherein the ceramide is at least one selected from the group consisting of ceramide-1, ceramide-3, ceramide-3B, ceramide-4, ceramide-6, myristoyl/palmitoyl oxostearamide/arachamide MEA, and dihydroxyisopropyl palmoylpalmamide; the sterol is at least one selected from the group consisting of cholesterol, cholesteryl acetate, cholesteryl sulfate, and phytosterol; the<!-- EPO <DP n="29"> --> fatty acid or fatty alcohol is a fatty acid or fatty alcohol having 14 to 22 carbon atoms; and the emulsifier is at least one selected from the group consisting of hydrogenated lecithin, polyglyceryl fatty acid ester, sorbitan fatty acid ester, polyoxyethylene glyceryl fatty acid ester, alkyl glucoside, and polyoxyethylene sorbitan fatty acid ester.</claim-text></claim><claim id="c-en-0005" num="0005"><claim-text>The weakly acidic composition of claim 1, wherein the pH adjuster is carbomer.</claim-text></claim><claim id="c-en-0006" num="0006"><claim-text>The weakly acidic composition of claim 5, wherein the polymeric thickener is at least one selected from the group consisting of hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose stearoxy ether, ammonium acryloyldimethyl taurate/VP copolymer, xanthan gum, and acrylate/alkyl acrylate crosspolymer.</claim-text></claim><claim id="c-en-0007" num="0007"><claim-text>A cosmetic formulation as a basic cosmetic product or a makeup cosmetic product, which comprises 1-99 wt% of the weakly acidic composition for skin external application according to any one of claims 1 to 6.</claim-text></claim></claims><drawings mxw-id="PDW20423177" load-source="patent-office"><!-- EPO <DP n="30"> --><figure id="f0001" num="1,2"><img id="if0001" file="imgf0001.tif" wi="140" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="31"> --><figure id="f0002" num="3,4"><img id="if0002" file="imgf0002.tif" wi="137" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="32"> --><figure id="f0003" num="5,6"><img id="if0003" file="imgf0003.tif" wi="130" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="33"> --><figure id="f0004" num="7,8"><img id="if0004" file="imgf0004.tif" wi="138" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="34"> --><figure id="f0005" num="9"><img id="if0005" file="imgf0005.tif" wi="147" he="131" img-content="drawing" img-format="tif"/></figure></drawings><search-report-data><doc-page id="srep0001" file="srep0001.tif" wi="152" he="233" type="tif"/><doc-page id="srep0002" file="srep0002.tif" wi="154" he="233" type="tif"/></search-report-data><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
